SCHEMBL5715052

SCHEMBL5715052

Cn1ccnc1SCc1ccc(OC(=O)N2CCN(Cc3ccc(C(=O)O)cn3)CC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.49
HDAC1 Q13547 1/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
MEN1 O00255 1/20 0.39
HSP90AA1 P07900 1/20 0.39
HSP90AB1 P08238 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
THRB P10828 1/20 0.39
PABPC1 P11940 1/20 0.39
HPGD P15428 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
KMT2A Q03164 1/20 0.39
HSD17B10 Q99714 1/20 0.39
POLB P06746 1/20 0.37
MGLL Q99685 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5715079 0.92 MAPT (0.40) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1
SCHEMBL5713998 0.91 SMN1; SMN2 (0.47) SMN1; SMN2HDAC1NPC1RAB9AKDM4E
SCHEMBL5715041 0.86 SMN1; SMN2 (0.51) SMN1; SMN2HDAC1NPC1RAB9AKDM4E
SCHEMBL5715380 0.86 KDM4E (0.51) SMN1; SMN2HDAC1KDM4EALDH1A1MEN1
SCHEMBL5714712 0.85 SMN1; SMN2 (0.47) SMN1; SMN2HDAC1NPC1RAB9AKDM4E
SCHEMBL5714454 0.85 SMN1; SMN2 (0.47) SMN1; SMN2HDAC1NPC1RAB9AKDM4E
SCHEMBL5714265 0.84 SIGMAR1 (0.42) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1
SCHEMBL5715376 0.82 SMN1; SMN2 (0.46) SMN1; SMN2HDAC1NPC1RAB9AALDH1A1
SCHEMBL5714661 0.82 HDAC1 (0.39) SMN1; SMN2HDAC1NPC1RAB9AKDM4E
SCHEMBL5715317 0.82 SMN1; SMN2 (0.46) SMN1; SMN2HDAC1NPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006527212-A 2006-11-30 JP claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160820-A1 Substituted piperazine carbamates LIPE, PNLIP, LPL SMN1; SMN2 3125/4885HDAC1 166/4885NPC1 624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.